New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. [electronic resource]
Producer: 20110228Description: 669-72 p. digitalISSN:- 1098-9064
- Adult
- Antibodies, Monoclonal -- immunology
- Antibodies, Monoclonal, Humanized
- Complement C3b Inactivator Proteins -- genetics
- Complement C5 -- immunology
- Complement Factor H -- genetics
- Complement Pathway, Alternative -- drug effects
- Female
- Gene Deletion
- Hemolytic-Uremic Syndrome -- drug therapy
- Humans
- Mutation
- Polymorphism, Genetic
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.